Arrowstreet Capital
CYCN icon

Arrowstreet Capital’s Cyclerion Therapeutics CYCN Stock Holding History

Arrowstreet Capital’s Portfolio CYCN Stock Details CYCN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-1,171
Closed -$138K – 2362
2020
Q2 		$138K Buy
+1,171
New +$97.9K ﹤0.01% 2203

Other funds holding CYCN

SPC
Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
MP
MFN Partners Boston, Massachusetts $4.77B AUM 72.29% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Arrowstreet Capital's CYCN Position: Q3 2020 in Review

Arrowstreet Capital sold out of Cyclerion Therapeutics (CYCN) in Q3 2020, closing a stake of 1,171 shares — an estimated $138K sold.

Arrowstreet Capital first reported a position in CYCN in Q2 2020 and held it in 1 quarter. The position peaked at $138K in Q2 2020. 73 funds tracked by Wall St. Rank hold CYCN as of Q3 2020.

  • Arrowstreet Capital reported no remaining Cyclerion Therapeutics position as of Q3 2020 after selling out during the quarter.
  • Arrowstreet Capital sold 1,171 Cyclerion Therapeutics shares in Q3 2020, an estimated $138K.
  • Arrowstreet Capital first reported a position in Cyclerion Therapeutics in Q2 2020 and held it in 1 quarter.
  • Arrowstreet Capital's Cyclerion Therapeutics position peaked at $138K in Q2 2020.
  • 73 funds tracked by Wall St. Rank held Cyclerion Therapeutics as of Q3 2020.

Based on Arrowstreet Capital's 13F filing for Q3 2020, filed 12 Nov 2020.